

The α_{2A} -adrenergic receptor (*ADRA2A*) modulates susceptibility to Raynaud's syndrome

Anniina Tervi^{1*}, Markus Ramste^{2*}, Erik Abner³, Paul Cheng², Jacqueline M. Lane^{4,5,6}, Matthew Maher⁵, Vilma Lammi¹, Satu Strausz¹, Trieu Nguyen², Mauro Lago Docampo^{8,14}, Wenduo Gu², *FinnGen*, *Estonian biobank research team*, Tõnu Esko³, Richa Saxena^{5,6,7}, Aarno Palotie^{1,9,10,11}, Samuli Ripatti^{1,5,12}, Nasa Sinnott-Armstrong¹³, Mark Daly^{1,9,10,11}, Marlene Rabinovitch¹⁴, Caroline A. Heckman¹, Thomas Quertermous², Samuel E. Jones¹, Hanna M. Ollila^{1,5,6,7}

1. Institute for Molecular Medicine Finland FIMM, Helsinki Institute of Life Science - HiLIFE, University of Helsinki, Helsinki, Finland
2. Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA 94305
3. Institute of Genomics, University of Tartu, Tartu, Estonia
4. Division of Sleep and Circadian Disorders, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
5. Broad Institute of MIT and Harvard, Cambridge, MA, USA
6. Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
7. Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
8. Stanford Cardiovascular Institute, Stanford University School of Medicine, CA.
9. Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA
10. Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA
11. Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
12. Public Health, Faculty of Medicine, University of Helsinki, Helsinki, Finland
13. Herbold Computational Biology Program, Public Health Sciences Division, Fred Hutch, Seattle, WA, USA
14. Stanford Children's Health Betty Irene Moore Children's Heart Center, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA

*Equal contribution

Correspondence: anniina.tervi@helsinki.fi; hanna.m.ollila@helsinki.fi

Abstract

Raynaud's syndrome is a common dysautonomia where exposure to cold increases the vascular tone of distal arteries causing vasoconstriction and hypoxia particularly in the extremities. Current treatment options are limited and unspecific. Biological mechanisms leading to the phenotype remain uncharacterized. Using genetic and electronic health record data from the UK Biobank, the Mass-General Brigham Biobank, the Estonian Biobank, and the FinnGen study, we identified 11,605 individuals with a diagnosis for Raynaud's syndrome and 1,116,172 population controls. We found eight loci including endothelial nitric oxide synthase (*NOS3*), HLA, and a notable association at the α_{2A} -adrenergic receptor (*ADRA2A*) locus (rs7090046, $P = 3.93 \times 10^{-47}$), implicating adrenergic signaling as a major risk factor with Raynaud's syndrome. We further investigate the role of the variants and *ADRA2A* expression in functional and physiological models. *In silico* follow-up analysis revealed an expression quantitative trait locus (eQTL) that co-localized and increased *ADRA2A* gene expression in tissue specific manner in the distal arteries. Staining with RNA scope further clarified the specificity of *ADRA2A* expression in small vessels. We show by CRISPR gene editing that the SNP region modifies *ADRA2A* gene expression in pulmonary artery smooth muscle cells. Finally, we performed a functional contraction assay on smooth muscle cells in cold conditions and showed lower contraction in *ADRA2A*-deficient and higher contraction in *ADRA2A*-overexpressing smooth muscle cells. Our results indicate that Raynaud's syndrome is related to vascular function mediated by adrenergic signaling through *ADRA2A*. Our study highlights the power of genome-wide association testing as a discovery tool for poorly understood clinical endpoints and further clarifies the role of

adrenergic signaling in Raynaud's syndrome by fine-mapping, using *in vitro* genomic manipulations and functional validation in distal smooth muscle cell populations located in arterioles.

1 Main

2
3 The autonomic nervous system controls physiological functions in the body that are not
4 under direct voluntary control and are not typically consciously directed. The targets of
5 the autonomic nervous system include body temperature, heart rate, respiration, bowel
6 movements and digestion, sexual arousal, endocrine function, blood pressure regulation
7 and vascular tone. However, when the autonomic nervous system malfunctions, it can
8 lead to symptoms and diseases of dysautonomia, affecting many different functions of
9 the autonomic nervous system including vascular tone and blood pressure as seen with
10 Raynaud's syndrome (RS)¹.

11 RS has a clear and specific disease manifestation, where the exposure to cold
12 increases the vascular tone of distal arteries causing vasoconstriction, leading to
13 cyanosis and hypoxia particularly in fingers and toes². RS can be seen as an example
14 of a disease with clear component of dysautonomia. Furthermore, RS is a common
15 phenomenon, with an estimated prevalence of 3 to 5% in the global population³. RS
16 rarely causes clinically debilitating symptoms, but RS is diagnosed with a single code in
17 the international classification of diseases (ICD-10 I73.0⁴) making it possible to use
18 electronic health records to find individuals with clinically significant RS and
19 consequently understand RS disease manifestation, disease correlations and the
20 underlying biological mechanisms.

21 Moreover, the comorbidities of RS include symptoms of pulmonary hypertension in a
22 subset of patients, especially in patients with systemic sclerosis⁵⁻⁸. Consequently, RS
23 can manifest as a comorbidity of diseases with substantial clinical significance, such as

24 systemic sclerosis, lupus erythematosus, myalgic encephalomyelitis/chronic fatigue
25 syndrome, and most recently Long COVID⁹⁻¹¹. Elucidating the disease mechanisms
26 behind primary RS would potentially provide insight into diseases with dysautonomia¹².
27 Finally, RS has a relatively high hereditary component with estimated twin heritability
28 between 54-65%^{13,14}. This study is the first to examine genetic associations of RS
29 across multiple cohorts and with functional validation in cellular models.

30

31 Results

32 α_{2A} -adrenergic receptor associates with Raynaud's syndrome

33 Using genetic and electronic health record data from FinnGen data freeze 10 (R10), the
34 UK Biobank (UKB), the Estonian Biobank (EstBB), and the Mass General Brigham
35 Biobank (MGB), we identified a total of 11,605 individuals with diagnosis of RS and
36 1,116,172 controls. Demographic characteristics of in the study cohorts showed that the
37 majority of RS patients were females (73.3 %), in agreement with earlier reports^{15,3}, and
38 mean disease diagnosis age was at 49.6 years (Suppl. Table 1).

39 Genome-wide association analysis of RS identified eight loci, which included a notable
40 association at the α_{2A} -adrenergic receptor (*ADRA2A*) locus, which was seen
41 independently at genome-wide significant level ($P \leq 5 \times 10^{-8}$) in all four cohorts and was
42 further supported in the meta-analysis (rs7090046, P meta-analysis = 3.93×10^{-47} , beta
43 [SE] = 0.22 [0.02], Figure 1, Table 1, Suppl. Figs. 1&2, Suppl. Tables 2,3,4).

44 In our meta-analysis, additional seven loci were genome-wide significant ($P \leq 5 \times 10^{-8}$,
45 Table 1). The variant rs7706161 is an intergenic variant closest to and downstream from
46 *IRX1* (iroquois homeobox 1) gene. *IRX1* encodes for a homeobox gene involved in
47 finger development in model organisms¹⁶. Furthermore, rs3130968 at chromosome 6 is
48 located in the HLA region downstream from *HCG22* (HLA complex group 22) and
49 upstream from the *HLA-C* and *HLA-B* genes. The same variant has also been
50 associated with peripheral vascular disease¹⁷. Moreover, the lead genome-wide
51 significant variant in chromosome 7, rs3918226, is an intron variant for *NOS3* (nitric
52 oxide synthase 3/endothelial nitric oxide) 5' regulatory region. As endothelial nitric oxide
53 signaling (eNOS) is a canonical mechanism in vasoconstriction and dilation^{18,19,20}, our
54 findings indicate a role for eNOS as part of vasoconstriction also in RS.

55 Variant rs7601684 in chromosome 2 is located upstream from *RAB6C*, a member of the
56 RAS oncogene family. The other chromosome 2 variant, rs7559925, is an intron variant
57 for the *ACVR2A* gene (activin A receptor type 2A) that encodes for a receptor related to
58 activins, which are part of the TGF-beta (transforming growth factor-beta) family of
59 proteins. Additionally, variant rs2092504 in chromosome 1, an intronic variant in
60 transmembrane protein 51 (*TMEM51*), and variant rs191137443 in chromosome 4
61 upstream from protocadherin 10 gene (*PCDH10*) were genome-wide significant in our
62 meta-analysis. The association with rs7559925 was shown with immunological traits
63 such as lymphocyte counts²¹ whereas rs3918226 has been shown to be associated with
64 high blood pressure²².

65 While many of these variants discovered in this GWAS are related to vascular tone,
66 blood pressure or immune function, the *ADRA2A* locus stands out as a significant

67 association in all tested cohorts and biobanks, highlighting its importance in RS across
68 multiple population cohorts. *ADRA2A* encodes for the α_{2A} -adrenergic receptor, is
69 targeted by α -blockers, and has a downstream effect on lowering vascular tone and
70 consequently blood pressure²³⁻²⁸.




Figure 1. Meta-analysis. A. A Manhattan plot of RS meta-analysis combining UKB, FinnGen R10, MGB and EstBB. **B.** Locus zoom plots for regional association at the *ADRA2A* locus, lead variant rs7090046 and **C.** regional association at the *NOS3* locus, lead variant rs3918226. (Created with Biorender.com)

SNP	CHR	POS (b38)	Ref.	Alt.	Combined Alt.AF	P-value	Effect estimate (beta)	SE	Nearest gene
rs7090046	10	111101172	G	A	0.290	3.93×10^{-47}	0.209	0.015	<i>ADRA2A</i>
rs7706161	5	4047779	A	G	0.725	4.02×10^{-26}	-0.155	0.015	<i>IRX1</i>
rs3130968	6	31097294	T	C	0.147	7.48×10^{-16}	0.157	0.019	<i>C6orf15/HLA</i>
rs3918226	7	150993088	T	C	0.076	1.37×10^{-09}	0.148	0.024	<i>NOS3</i>
rs7559925	2	147883361	T	C	0.689	2.88×10^{-08}	-0.079	0.014	<i>ACVR2A</i>
rs191137443	4	132501888	T	C	0.006	2.99×10^{-08}	0.481	0.087	<i>PCDH10-DT</i>
rs2092504	1	15190856	T	C	0.415	3.08×10^{-08}	-0.076	0.014	<i>TMEM51</i>
rs7601792	2	129324147	A	G	0.0076	3.59×10^{-08}	0.590	0.107	<i>RAB6C</i>

Table 1. RS meta-analysis lead variants combining the UKB, FinnGen R10, MGB and EstBB data.

71 ***ADRA2A* RS risk variants increase *ADRA2A* expression**

72 To understand the functional consequences of the *ADRA2A* variants, we examined their
73 association with gene expression across human tissues and tissue specificity. Using
74 data from GTEx (<https://gtexportal.org/home/>), we observed that the lead variant
75 (rs7090046) affected the expression of *ADRA2A* in a tissue-specific manner in the tibial
76 arteries (rs7090046, eQTL $P = 1.3 \times 10^{-13}$, Figure 2) in contrast to coronary arteries ($P =$
77 0.16) or aorta ($P = 0.65$). In addition, the lead variant for *ADRA2A* expression in GTEx
78 in tibial arteries was rs1343449 (r^2 in Europeans with rs7090046 = 0.98), which was
79 also the lead variant in the MGB and among the five top variants in each cohort and the
80 credible set (Figure 2, Suppl. Table 2). A formal co-localization analysis suggested a

81 shared signal between RS and *ADRA2A* expression in tibial arteries specifically
 82 (posterior probability = 0.99, Figure 2, Suppl. Fig. 3, Suppl. Table 7). The risk allele
 83 associated with higher RS risk associated with higher *ADRA2A* expression in
 84 agreement with earlier role of adrenergic receptors regulating vascular wall
 85 contraction²⁹. Finally, we performed stratified LD score regression using ENCODE³⁰ to
 86 elucidate overall relevance of different tissues across the body in RS. We discovered
 87 the most significant associations with smooth muscle cell (SMC) types, further
 88 suggesting that possible pathology is mediated by SMCs (Suppl. Table 5).




Figure 2. *ADRA2A* expression. **A.** Genotype-tissue expression for SNP rs7090046 in tibial arteries) and **B.** across tissues from GTEx (NES = normalized expression values, m-value = posterior probability, $P \leq 0.05$). **C.** the RS association colocalizes with eQTL signal in tibial arteries. (created with Biorender.com)

89 ***ADRA2A* is specifically expressed in microvasculature**

90 Human arteries contain primarily fibroblasts, SMCs, pericytes (defined as cells found
91 around microvasculature), and endothelial cells. As *ADRA2A* eQTL suggests that the
92 variant affects expression in blood vessels in particular, we wanted to examine which
93 cell types express *ADRA2A* in the vascular wall. First, single cell RNA sequencing
94 (scRNAseq) data from human vascular tissue demonstrated that only a small cluster of
95 cells expresses *ADRA2A* (Figure 3B). This cluster expressing *ADRA2A* is distinct from
96 the medial smooth muscle cells (SMCs) that are the majority of the *MYH11*⁺, a classical
97 marker for medial smooth muscle cells that are found in the vessel wall (Figure 3B &
98 3D). Moreover, the cluster expressing *ADRA2A* contains cells that express mature SMC
99 genes, and in addition co-express *NOTCH3* (Figure 3B & 3C)^{31,32}. These findings
100 suggest that only microvascular cells express *ADRA2A* and are likely a causal cell
101 population for RS.

102 To further understand the role of the *ADRA2A* expressing cell population, we assessed
103 the expression of *ADRA2A* in 14 different primary vascular smooth muscle cells.
104 *ADRA2A* was found in only one line that was likely obtained from the pulmonary
105 microvasculature but *ADRA2A* expression was otherwise not detected in any other
106 vascular SMC lines derived from larger arteries including medium to large arteries
107 (Figure 3F & 3G). This particular cell line also expresses other markers of the
108 microvascular SMC population identified by scRNAseq, such as *NOTCH3* (Figure 3G).
109 Thus, this microvascular SMC line was chosen for subsequent functional studies.




Figure 3. *ADRA2A* expression is restricted to microvascular SMC. UMAP plot of human artery scRNAseq from human vascular atlas indicating **A.** cell type identities of all clusters, **B.** *ADRA2A* expression, **C.** Co-expression of *NOTCH3* in the same cluster **D.** and *MYH11* expression. **E.** Schematic of vascular wall and *ADRA2A* expression. **F.** RNA Scope against *ADRA2A* in distal human coronary arteries **G.** RT-PCR quantification of *ADRA2A* and *NOTCH3* expression HCASMs and PASMCs.

110 ***ADRA2A* expression affects SMC contraction in temperature dependent fashion**

111 Next, we examined how *ADRA2A* expression alters SMC contractility in conditions
112 mimicking RS and environmental cold stress. Earlier studies in temperature-dependent
113 vascular contraction have supported the role of the adrenergic system but have focused
114 nearly solely on the role of *ADRA2C* and its temperature-dependent activation^{26,33,34}.
115 These earlier studies and our findings raise an interesting question: Does *ADRA2A*
116 directly affect vascular contraction? To test this, we used a collagen-based SMC
117 contraction assay in *ADRA2A* over-expressing or silenced cells. We discovered that in
118 cold conditions (+28°C), silenced siRNA-*ADRA2A* treated pulmonary artery SMCs
119 (PASMCS) contracted significantly less (Figure 4A). However, *ADRA2C* silencing did
120 not attenuate cold induced contraction in a similar manner to *ADRA2A* (Figure 4A). In
121 warm conditions, both *ADRA2A* and *ADRA2C* silenced SMCs contracted similarly
122 (Figure 4B). Consequently, upon lentiviral overexpression of *ADRA2A*, we observed
123 that the PASMCS contracted significantly more (Figure 4C, D) overall suggesting that
124 *ADRA2A* was affecting contraction in a dose dependent fashion and was responsible for
125 cold induced contraction.




Figure 4. ADRA2A expression affects SMC contraction upon cold stimulus (+28°C). A. *ADRA2A* and *ADRA2C* silencing in cold exposure B. *ADRA2A* and *ADRA2C* silencing and in ambient conditions C. *ADRA2A* and *ADRA2C* overexpression in cold exposure D. *ADRA2A* and *ADRA2C* overexpression in ambient conditions. Mean +/- SEM, *** $P < 0.0005$, ** $P < 0.005$ & * $P < 0.05$.

126 **CRISPR interference targeting rs7090046 supports *ADRA2A*'s role as a causal**
127 **gene for RS**

128 We then used this cell line to study *ADRA2A* gene causality in RS. To elucidate
129 mechanistic importance of the *ADRA2A* rs7090046 locus, we designed five CRISPR
130 guides targeting the lead SNP variant rs7090046 and used the CRISPRi-Cas9
131 machinery to interfere signaling from this variant region. We observed a significant
132 decrease in *ADRA2A* gene expression 5 days after the lentiviral treatment on the
133 PSMCs suggesting that the region is needed for controlling *ADRA2A* expression
134 (Figure 5).




Figure 5. CRISPR interference against rs7090046 supports causal role of *ADRA2A*. A. Schematic of the CRISPR interference experiment. B. RT-PCR quantification of *ADRA2A* expression in rs7090046 guide targeted cells vs CTRL. Mean +/- SEM, ***P<0.0005, **P<0.005 & *P<0.05.




Figure 6. Schematic of the proposed RS –associated pathomechanism. We propose a possible mechanism based on our observations from genetic and contraction assays. In this hypothesized model, the pathomechanism of RS is dependent on *ADRA2A* expression. In normal physiological conditions, it is well established that cold or stress both induce secretion of the ligands that bind the adrenergic receptors. Consequently, these ligands such as epinephrine and norepinephrine activate the adrenergic system. In RS patients, the expression of *ADRA2A* gene encoding α 2A-adrenergic receptor is higher and similarly the amount of α 2A-adrenergic receptor available for ligand binding on microvascular SMCs. Increase in SMC *ADRA2A* expression sensitizes the postsynaptic system that aggravates adrenergic effects of SMC contraction. In conditions such as cold and stress where more ligand is released the contraction is further accentuated. Black arrows representing adrenergic downstream signaling strength.

135 Discussion

136

137 We performed a meta-analysis of RS across four cohorts and identified genome-wide
138 significant associations with RS at *ADRA2A*, *HLA*, *NOS3*, *RAB6C*, *ACVR2A*, *PCDH10*,
139 *TMEM51* and *IRX1* loci. The most prominent genetic association with RS was
140 discovered in the *ADRA2A* locus. Furthermore, this association was significant
141 independently in all cohorts, highlighting the significance of *ADRA2A* in RS. *In silico*
142 follow-up analysis of *ADRA2A* RNA expression across tissues showed the highest
143 expression in tibial arteries, and single cell expression analysis further supported the
144 role of SMCs as the key cell type for *ADRA2A* expression. Finally, functional contraction
145 assay in SMCs in cold conditions showed lower contraction in *ADRA2A*-deficient and
146 higher contraction in *ADRA2A* overexpressing SMCs. Overall, our findings indicate
147 *ADRA2A* in RS and as a regulator of vascular contraction in SMCs in temperature
148 dependent fashion.

149 The strongest association in this study is a robust signal from *ADRA2A* in all four
150 cohorts and with the same lead signals across cohorts. Furthermore, the lead variants
151 are located in a regulatory region that affected *ADRA2A* expression in distal arteries in
152 particular. In addition, we identified a specific subpopulation of SMCs that specifically
153 expresses the α_{2A} -adrenergic receptor. While the adrenergic system has been
154 suggested as a potential pathological mechanism underlying RS^{23,24,26,27,33-41}, these
155 earlier studies have focused almost solely on the α_{2C} -adrenergic receptor. Interestingly,
156 a recent preliminary descriptive biobank study has identified some of the same RS
157 loci⁴². In this study, we assessed contraction SMCs after *ADRA2A* or *ADRA2C* siRNA

158 knockdown in human SMCs. We saw a robust contraction upon cold with *ADRA2A*
159 knockdown whereas *ADRA2C* silencing did not attenuate cold induced contraction in a
160 similar manner to *ADRA2A*. Overall, these findings suggest an independent role of
161 *ADRA2A* in vascular contraction and in temperature-dependent control of vascular tone.

162 In cold or stress conditions, norepinephrine and epinephrine are released and bind to
163 adrenergic receptors throughout the body, which exerts various effects: dilating pupils
164 and bronchioles, increase in heart rate, and in blood vessels constriction. The blood
165 vessels constriction is mediated by the SMC that express adrenergic receptors on their
166 surface. In healthy patients without RS, there are mechanisms to prevent unwanted and
167 excessive vessel contraction. First, the cell constriction (upon cold or stress) can be
168 limited by the increased release of ligand by translocation of the α_{2C} -adrenergic receptor
169 from the cytosol to the cell surface. Second, α_{2A} -adrenergic receptors are also
170 expressed on the presynaptic membrane and function there as a negative feedback
171 loop for catecholamine release⁴³.

172 Based on our results we propose a new model explaining the pathomechanism of RS
173 that underlines the power of human genetics driven studies for understanding disease
174 mechanisms. Our SMC contraction assays show that cold induced SMC contractility
175 was modified by *ADRA2A* expression. Furthermore, we combined functional studies
176 with the genomics-driven discovery that genetic variation at the *ADRA2A* locus leads to
177 increased expression of α_{2A} -adrenergic receptor in a population of SMCs. Such an
178 increase in *ADRA2A* expression may sensitize these cells to adrenergic response and
179 lead to increased signaling through the adrenergic pathway (Figure 6).

180 In addition to the signal from the adrenergic system, our meta-analysis indicated other
181 signals and in particular endothelial nitric oxide synthase (eNOS) that clarify the
182 pathological mechanisms with RS. Nitric oxide itself is a well-known mediator of
183 vasodilation in arteries⁴⁴. Therefore, it has been suggested as one of the underlying
184 pathological mechanisms in RS although the role of it is still unclear^{2,45,46}. These genetic
185 associations may also elucidate the more specific disease mechanisms or even provide
186 insight into the heterogeneity of the symptomatology in RS. For example, the signal
187 from chromosome 6, HLA class I region, points towards the possible immune, infectious
188 or autoimmune mechanisms in RS. It is still unclear, however, if this signal is a signal
189 from autoimmune diseases that have secondary RS and not primary Raynaud's disease
190 per se^{47,48}, which was also indicated by Hartmann *et al.* (2023) in the UKB⁴². As for the
191 other signals detected by our meta-analysis, *IRX1* gene has been implied in the
192 embryonic development and in the development of fingers and digits which are affected
193 in RS^{49,50} as well as a tumor suppression gene⁵¹⁻⁵⁴. Variants in *ACVR2A*, *RAB6C*,
194 *PCDH10* and *TMEM51* have been implied in immunological traits, cell cycle,
195 neurological disease and contractile function in cardio myocytes, respectively^{21,55-57}.

196 Our study should be interpreted within the following limitations. Only a subset of
197 individuals with RS have symptoms that are recognized or need treatment and we are
198 likely missing the more benign spectrum of symptoms in the current population. Our
199 findings are limited to individuals with European ancestry. Finally, data from
200 subcutaneous microvascular cells or microvascular cells from RS patients were not
201 available for this study and any genetic or expression effects might be accentuated or
202 changed after disease onset in RS patients.

203 To summarize, we report here a robust association with *ADRA2A* with functional follow-
204 up of this locus. In addition, we discovered seven loci that can be followed up in future
205 functional studies. Our findings not only point towards the vascular pathophysiology
206 underlying RS, but also specifically to the dysfunction of the autonomic nervous system
207 and its dialogue with the vascular structure. Our results also suggest that the
208 pathophysiological RS phenotype can be mediated through multiple possibly additive
209 mechanisms involving adrenergic signaling, immune mechanisms and nitric oxide action
210 and are in agreement with earlier studies. We highlight *ADRA2A* in the adrenergic
211 system as a likely causal gene in a subset of microvascular SMCs, where we suggest it
212 sensitizes these cells for catecholamines. Due to its localized expression in this subset
213 of cells and the dose-dependent nature of the pathological phenotype as demonstrated
214 by the genetic data, *ADRA2A* may be a promising target for further pharmaceutical
215 studies.

216

217 Materials and Methods

218

219 Genetic analyses

220

221 Cohorts

222

223 FinnGen is a public-private partnership registry-based study of Finnish residents
224 combining genetic and electronic health record data from different registers, for example,
225 primary care and hospital in- and out-patient visits. The release 10 (R10) contains data
226 on up to 412,181 participants, primarily of Finnish ancestry from newborns to the age of

227 104 at baseline recruitment. The aim of the study is to collect the data of 500,000 Finns
228 representing 10% of the population of Finland (for more information see
229 <https://www.finngen.fi/en>).

230 The UK Biobank (UKB) is a population-based study containing over 500,000 individuals
231 of mainly European ancestry⁵⁸. The participants were recruited to the study between 2006
232 to 2010, were aged between 37 to 73 years of age and were residents of the United
233 Kingdom. The study is a combination of, for example, different lifestyle measures,
234 genotypes, electronic health record data, blood count data and questionnaire data, and
235 the data is updated frequently to capture the health trajectories of participated individuals.

236 The Estonian Biobank is a population-based biobank with 212,955 participants in the
237 current data freeze (2023v1). All biobank participants have signed a broad informed
238 consent form and information on ICD-10 codes is obtained via regular linking with the
239 national Health Insurance Fund and other relevant databases, with majority of the
240 electronic health records having been collected since 2004⁵⁹.

241 The Mass-General Brigham (MGB) Biobank (formerly Partners HealthCare Biobank) is
242 a hospital-based cohort study from the MGB healthcare network in Boston (MA, USA)
243 with electronic health record (EHR), genetic, and lifestyle data⁶⁰⁻⁶². The MGB Biobank
244 includes data obtained from patients in several community-based primary care facilities
245 and specialty tertiary care centers in Boston, MA^{60,63}.

246 Ethics statement

247

248 Patients and control subjects in FinnGen provided informed consent for biobank
249 research, based on the Finnish Biobank Act. Alternatively, separate research cohorts,
250 collected prior the Finnish Biobank Act came into effect (in September 2013) and start
251 of FinnGen (August 2017), were collected based on study-specific consents and later
252 transferred to the Finnish biobanks after approval by Fimea (Finnish Medicines
253 Agency), the National Supervisory Authority for Welfare and Health. Recruitment
254 protocols followed the biobank protocols approved by Fimea. The Coordinating Ethics
255 Committee of the Hospital District of Helsinki and Uusimaa (HUS) statement number for
256 the FinnGen study is Nr HUS/990/2017.

257 The FinnGen study is approved by Finnish Institute for Health and Welfare (permit
258 numbers: THL/2031/6.02.00/2017, THL/1101/5.05.00/2017, THL/341/6.02.00/2018,
259 THL/2222/6.02.00/2018, THL/283/6.02.00/2019, THL/1721/5.05.00/2019 and
260 THL/1524/5.05.00/2020), Digital and population data service agency (permit numbers:
261 VRK43431/2017-3, VRK/6909/2018-3, VRK/4415/2019-3), the Social Insurance
262 Institution (permit numbers: KELA 58/522/2017, KELA 131/522/2018, KELA
263 70/522/2019, KELA 98/522/2019, KELA 134/522/2019, KELA 138/522/2019, KELA
264 2/522/2020, KELA 16/522/2020), Findata permit numbers THL/2364/14.02/2020,
265 THL/4055/14.06.00/2020, THL/3433/14.06.00/2020, THL/4432/14.06/2020,
266 THL/5189/14.06/2020, THL/5894/14.06.00/2020, THL/6619/14.06.00/2020,
267 THL/209/14.06.00/2021, THL/688/14.06.00/2021,
268 THL/1284/14.06.00/2021, THL/1965/14.06.00/2021, THL/5546/14.02.00/2020 and

269 Statistics Finland (permit numbers: TK-53-1041-17 and TK/143/07.03.00/2020 (earlier
270 TK-53-90-20)).

271 The Biobank Access Decisions for FinnGen samples and data utilized in FinnGen Data
272 Freeze7 include: THL Biobank BB2017_55, BB2017_111, BB2018_19, BB_2018_34,
273 BB_2018_67, BB2018_71, BB2019_7, BB2019_8, BB2019_26, BB2020_1, Finnish Red
274 Cross Blood Service Biobank 7.12.2017, Helsinki Biobank HUS/359/2017, Auria
275 Biobank AB17-5154 and amendment #1 (August 17 2020), Biobank Borealis of
276 Northern Finland_2017_1013, Biobank of Eastern Finland 1186/2018 and amendment
277 22 § /2020, Finnish Clinical Biobank Tampere MH0004 and amendments (21.02.2020
278 06.10.2020), Central Finland Biobank 1-2017, and Terveystalo Biobank STB
279 2018001.2.

280 The activities of the EstBB are regulated by the Human Genes Research Act, which
281 was adopted in 2000 specifically for the operations of the EstBB. Individual level data
282 analysis in the EstBB was carried out under ethical approval 1.1-12/624 from the
283 Estonian Committee on Bioethics and Human Research (Estonian Ministry of Social
284 Affairs), using data according to release application 6-7/GI/16279 from the Estonian
285 Biobank.

286 The North West Multi-centre Research Ethics Committee (MREC) has granted the
287 Research Tissue Bank (RTB) approval for the UKB that covers the collection and
288 distribution of data and samples (<http://www.ukbiobank.ac.uk/ethics/>). Our work was
289 performed under the UKB application number 22627 (Principal Investigator Dr Matti
290 Pirinen, FIMM). All participants included in the conducted analyses have given a written
291 consent to participate.

292 The MGB has obtained a Certificate of Confidentiality. In addition, The MGB works in
293 close collaboration with the Partners Human Research Committee (PHRC) (the
294 Institutional Review Board). This collaboration has ensured that the Biobank's actions and
295 procedures meet the ethical standards for research with human subjects. Biobank
296 patients are recruited from inpatient stays, emergency department settings, outpatient
297 visits, and electronically through a secure online portal for patients. Recruitment and
298 consent materials are fully translated in Spanish to promote patient inclusion. The
299 systematic enrollment of patients across the MGB network and the active inclusion of
300 patients from diverse backgrounds contribute to a Biobank reflective of the overall
301 demographic of the population receiving care within the MGB network. Recruitment for
302 the Biobank launched in 2009 and is ongoing through both in-person recruitment at
303 participating clinics and electronically through the patient portal. The recruitment strategy
304 has been described previously⁶⁰. All recruited patients provided written consent upon
305 enrollment, and are offered an option to refuse consent.

306

307 Genotyping and quality control

308

309 Genotyping in the FinnGen cohort was performed by using Illumina (Illumina Inc., San
310 Diego, CA, USA) and Affymetrix arrays (Thermo Fisher Scientific, Santa Clara, CA,
311 USA) and lifted over to build version 38 (GRCh38/hg38)⁶⁴. Individuals with high
312 genotype absence (> 5%), inexplicit sex or excess heterozygosity (+-4 standard
313 deviations) were excluded from the data⁶⁴. Additionally, variants that had high absence
314 (> 2%), low minor allele count (< 3) or low Hardy-Weinberg Equilibrium (HWE) ($P <$

315 1×10^{-06}) were removed. More detailed explanations of the genotyping, quality control
316 and the genotype imputation are provided elsewhere⁶⁴. All individuals in the cohort were
317 Finns and matched against the SiSu v4 reference panel (<http://www.sisuproject.fi/>).

318 All the EstBB participants have been genotyped at the Core Genotyping Lab of the
319 Institute of Genomics, University of Tartu, using Illumina Global Screening Array
320 v3.0_EST. Samples were genotyped and PLINK format files were created using Illumina
321 GenomeStudio v2.0.4. Individuals were excluded from the analysis if their call-rate was
322 $< 95\%$, if they were outliers of the absolute value of heterozygosity ($> 3SD$ from the
323 mean) or if sex defined based on heterozygosity of X chromosome did not match sex in
324 phenotype data. Before imputation, variants were filtered by call-rate $< 95\%$, HWE P-
325 value $< 1 \times 10^{-04}$ (autosomal variants only), and minor allele frequency $< 1\%$. Genotyped
326 variant positions were in build 37 and were lifted over to build 38 using Picard. Phasing
327 was performed using the Beagle v5.4 software⁶⁵. Imputation was performed with Beagle
328 v5.4 software (beagle.22Jul22.46e.jar) and default settings. Dataset was split into
329 batches 5,000. A population specific reference panel consisting of 2,695 WGS samples
330 was utilized for imputation and standard Beagle hg38 recombination maps were
331 used. Based on principal component analysis, samples who were not of European
332 ancestry were removed. Duplicate and monozygous twin detection was performed with
333 KING 2.2.7⁶⁶, and one sample was removed out of the pair of duplicates. Analyses were
334 restricted to individuals with European ancestry.

335 The UKB genotyped 488,477 participants: 49,950 on the Affymetrix (Thermo Fisher
336 Scientific) UK BiLEVE Axiom Array and 438,427 on the highly similar Affymetrix UK
337 Biobank Axiom Array, These arrays captured up to 825,927 SNPs and short indels, with

338 variants prioritized for known coding variants, those previously associated with disease
339 and ancestry-specific markers that provide a good imputation backbone. DNA was
340 extracted from blood samples taken at baseline interviews, between 2006 and 2010,
341 and genotyping was carried out in 106 sequential batches, giving genotype calls for
342 812,428 unique variants in 489,212 participants. After removing high missingness and
343 very rare variants, as well as poor-quality samples, these genotypes were phased using
344 SHAPEIT3 and imputed to the Haplotype Reference Consortium (HRC) and to a
345 merged UK10K and 1000 Genomes phase 3 reference panel⁶⁷, both in genome
346 assembly GRCh37 using IMPUTE2. This resulted in 93,095,623 autosomal SNPs, short
347 indels and large structural variants in 487,442 individuals and 3,963,705 markers on the
348 X chromosome. For more details, see Bycroft *et al.* 2018⁵⁸.

349 The MGB genotyped 53,297 participants on the Illumina Global Screening Array ('GSA')
350 and 11,864 on Illumina Multi-Ethnic Global Array ("MEG"). The GSA arrays captured
351 approximately 652K SNPs and short indels, while the MEG arrays captured
352 approximately 1.38M SNPs and short indels. These genotypes were filtered for high
353 missingness ($> 2\%$) and variants out of HWE ($P < 1 \times 10^{-12}$), as well as variants with an
354 AF discordant ($P < 1 \times 10^{-150}$) from a synthesized AF calculated from GnomAD
355 subpopulation frequencies and a genome wide GnomAD model fit of the entire cohort.
356 This resulted in approximately 620K variants for GSA and 1.15M for MEG. The two sets
357 of genotypes were then separately phased and imputed on the TOPMed imputation
358 server (Minimac4 algorithm) using the TOPMed r2 reference panel. The resultant
359 imputation sets were both filtered at an $R^2 > 0.4$ and a $MAF > 0.001$, and then the two
360 sets were merged/intersected resulting in approximately 19.5M GRCh38 autosomal

361 variants. The sample set for analysis here was then restricted to just those classified as
362 EUR (N = 54,452) according to a metric of being +/- 2 SDs of the average EUR
363 sample's principal components 1 to 4 in the HGDP reference panel.

364

365 Phenotype definition

366

367 We built the phenotype for RS using ICD10 code I73.0 in all of our cohorts (see Suppl.
368 Table 1 for the total number of cases and controls in each cohort used). Additionally, we
369 used the self-reported measures and primary care codes of RS in the UKB, and the
370 ICD-9 code 4430 in the FinnGen R10 and the UKB.

371 For FinnGen R10 phenotype definition, we used both the hospital record data (inpatient
372 N = 88 (4.2%) cases and outpatient N = 1,204 (57.8%) cases) and primary care data (N
373 = 792 (38.0%)). Most of the cases (N = 2,025 (87.75%)) in the EstBB were from primary
374 care data setting, and the rest were from hospital record data (N = 180 (12.25%)).

375 From the UKB data, we obtained both self-reported and electronic health record data for
376 disease definitions. To define the phenotypes, we used data from the self-report non-
377 cancer illness codes (data field 20002), which were assessed during the baseline
378 interview, hospital inpatient records (HES; data field 41234) and primary care diagnosis
379 records (data field 42040). For RS, code 1561 was used from the self-reported data.

380 From the hospital inpatient data, we included individuals as a case for the phenotype if
381 they had I73.0 ICD-10 or 4430 ICD-9 diagnosis code. In the primary care data,
382 diagnoses are coded using the NHS-specific Read v2 or CTV3 codes instead of the
383 ICD-coding. We used the following Read codes to define the respective phenotype:

384 - Read v2: “G730.”, “G7301”, “G7300” or “G730z”

385 - Read CTV3 (v3): “G730.”, “XE0VQ”, “G7300”, “G730z”, “G7301”, “X7051” or
386 “XE0XA”

387 With this definition for RS, we ended up with 5,162 cases and 440,833 controls of
388 European ancestry. Most of the cases for RS came from the primary care data (N =
389 2,953 (57.2%)) and hospital inpatient data (N = 1,664 (32.2%)).

390

391 GWAS

392

393 For the FinnGen cohort, GWAS was conducted using the REGENIE (v.2.2.4) pipeline
394 for R10 data⁶⁸ (<https://github.com/FINNGEN/regenie-pipelines>). Analysis was adjusted
395 for age at death or end of follow up (12.31.2021), sex, genotyping batches and the first
396 10 genetic principal components. Firth approximation was applied for variants with
397 association P-value < 0.01.

398 The UKB GWA analyses were performed using REGENIE v3.1.1⁶⁸. The whole-genome
399 regression model (step 1) was created using 524,307 high-quality genotyped SNPs (bi-
400 allelic; MAF ≥ 1%; HWE P > 1x10⁻⁰⁶; present in all genotype batches, total missingness
401 < 1.5% and not in a region of long-range LD⁶⁹ with the leave-one-chromosome-out (--
402 loocv) option enabled. We corrected for the following covariates:

403 - age at follow-up end (2019.08.18) or death (if earlier than follow-up end),
404 calculated as the difference in years between the 15th day of month and year of
405 birth (data fields 52 and 34, respectively) and the follow-up end or death date.

- 406 - sex (data field 31)
- 407 - genotyping array (categorical), derived from genotyping batch (data field 20000),
- 408 as “UKB BiLEVE” (batches -11 to -1), “UKB Axiom release 1” (1 to 22) and “UKB
- 409 Axiom release 2” (23 to 95).
- 410 - genetic principal components 1 to 10 (data field 22009)
- 411 - centre of baseline visit (categorical; data field 54)

412 The GWA (step 2) was performed using v3 imputed genotypes⁵⁸ for chromosomes 1-22
413 and X with the approximate Firth correction applied for variants with association P-value
414 < 0.05 (default setting), using the flags --firth, --approx and --firth-se. After analysis with
415 REGENIE, we excluded results for imputed variants with MAF < 0.1% and/or imputation
416 INFO < 0.3.

417 Association analysis in the EstBB was carried out for all variants with an INFO score >
418 0.4 using the additive model as implemented in REGENIE v3.0.3 with standard binary
419 trait settings⁶⁸. Logistic regression was carried out with adjustment for current age, age²,
420 sex and 10 first genetic principal components as covariates, analyzing only variants with
421 a minimum minor allele count of 2.

422 In the MGB, the association analysis was carried out using REGENIE v3.2.2⁶⁸, with
423 covariates of Age, Sex, Genotype-Chip and five first principal components of ancestry
424 calculated on just the analysis set (EUR only) of samples, analyzing only variants with a
425 minimum minor allele count of 10.

426 Manhattan-plots for all the cohorts’ GWASs and meta-analyses were plotted using R
427 version 4.0.1 (packages: qqman and RColorBrewer).

428

429 Meta-analysis

430

431 Meta-analyses were conducted using METAL

432 (https://genome.sph.umich.edu/wiki/METAL_Documentation) with standard settings,

433 and tracking allele frequency with the AVERAGEFREQ option and analyzing

434 heterogeneity between used summary statistics with the ANALYZE HETEROGENEITY

435 option. Summary statistics from different cohorts were matched against rsIDs. Both

436 sample size based meta-analysis and effect estimate based analyses were run (Figure

437 1, Table 1 & Suppl. Table 3). Locus zoom plots from the meta-analysis results were

438 created using the LocusZoom web browser (<https://github.com/statgen/locuszoom>)⁷⁰.

439

440 eQTL and co-localization analyses

441

442 We conducted the eQTL analysis by using the web browser of the GTEx project

443 (<https://gtexportal.org/home/>)⁷¹. Co-localization analyses were performed using the

444 coloc R package (v5.1.0.1)^{72,73} in R v4.2.2. We extracted all variants in a 200kb region

445 centered on the lead variant and imported the same region from GTEx v8⁷¹ eQTL

446 association statistics. We then tested the co-localization between RS and each of the 49

447 tissues and generated co-localization plots using the LocusCompareR R package

448 (v1.0.0)⁷⁴ using LD r^2 from 1000 Genomes European-ancestry samples.

449

450 Functional assays

451

452 RNA extraction and RT-PCR

453

454 RNA was isolated according to manufacturer's instructions using RNeasy plus micro kit
455 (Qiagen, #74034). The quality of the RNA was determined with Nanodrop ND-1000
456 (Thermo Fisher Scientific), and 500 ng of total RNA was used for cDNA synthesis using
457 High-capacity RNA-to-cDNA kit (Life Technologies, #4388950) on a BIO-RAD C1000
458 thermal cycler. RT-qPCR was performed using Taqman probes for *ADRA2A*
459 (Hs01099503), *ADRA2C* (Hs03044628) and *NOTCH3* (Hs01128537) according to the
460 manufacturer's instructions on a ViiA7 Real-Time PCR system (Applied Biosystems,
461 Foster City, CA). GAPDH and UBC were used to normalize relative expression levels.
462 The $2^{-\Delta\Delta Ct}$ method was used to quantify relative gene expression levels. Technical
463 triplicates of Ct values were averaged for each sample and normalized to the
464 housekeeping gene. Expression levels of mRNA are presented as fold change (control
465 group = 1).

466 SiRNA and lentiviral overexpression
467

468 For siRNA transfection, cells were 60% confluent when treated with siRNA or scramble
469 control to a final concentration of 20 nM with RNAiMax (Invitrogen, Carlsbad, CA). The
470 siRNAs for *ADRA2A* (Cat # L-005422-00-0005) and *ADRA2C* (Cat # L-005424-00-0005)
471 were purchased from Dharmacon (ONTARGET plus SMART pool siRNA). Cells were
472 treated with an equimolar combination of Silencer and Scramble and collected 72 hours
473 after transfection.

474 For overexpression studies *ADRA2A* (Human Tagged ORF Clone in pLenti-C-Myc-DDK
475 Lentiviral Gene Expression Vector, NM_000681) and *ADRA2C* (Human Tagged ORF
476 Clone in pLenti-C-Myc-DDK Lentiviral Gene Expression Vector, NM_000683) plasmids
477 were purchased from OriGene Technologies. To package viruses 8.5×10^5 HEK293T cells
478 plated in each well of a six-well plate. The following day, lentiviral gene expression vectors
479 were co-transfected with second generation lentivirus packaging plasmids, pMD2.G and
480 pCMV-dR8.91, into cells using Lipofectamine 3000 (Thermo Fisher, L3000015) according
481 to the manufacturer's instructions. ViralBoost Reagent (AllStem Cell Advancements,
482 VB100) was added (1:500) with fresh media after 5 hours. Supernatant containing viral
483 particles was collected 48 hours after transfection and filtered. PSMCs were transduced
484 with high MOI and treated for 12 hours and collected 72 hours after transfection.

485 RNAscope

486

487 Frozen sections of human coronary arteries were processed according to the

488 manufacturer's instructions, and all reagents were obtained from ACD Bio (Newark, CA).

489 Sections were incubated with commercially available probes against human *ADRA2A*

490 (#602791). Colorimetric assays were performed per the manufacturer's instructions.

491

492 Single-cell RNA sequencing (scRNAseq) from human tissue

493

494 scRNAseq data was obtained from the human vascular atlas available on

495 <https://cellxgene.cziscience.com/>.

496

497 Smooth muscle cell contraction assay

498

499 Pulmonary arterial SMCs were transfected with either scrambled siRNA or siADRA2A,

500 siADRA2C or combination of both. Following 48 hours of transfection, cells were

501 trypsinized and collected to be used for a collagen-based cell contraction assay Cyto-

502 Select 48-well Cell Contraction Assay Kit (Cell Biolabs, San Diego, CA). In the assay, a

503 mixture the pulmonary SMCs (3×10^6 /ml) and cold Collagen Gel Working Solution was

504 incubated in a 48-well dish at 37°C for 1 hour to induce optimal polymerization following

505 the manufacturer's instructions. Next, cell culture medium with added SMC contraction

506 agent or without was added on top of each well already containing the polymerized cell

507 and collagen mixture. The cells were then incubated at either 28 °C or at 37°C, 5% CO₂.

508 After 48 hours, the Keyence slide scanning microscope BZ-X810 was used to image the
509 wells and cell contraction was measured using ImageJ by drawing the outlines of the gel,
510 calculating the gel area, and comparing it to the well area.

511

512 Generation and analysis of CRIPSR lines

513

514 Genome editing of the region around rs7090046 was performed by CRISPRi/dCas9-
515 KRAB system as previously reported⁷⁴. The guide RNAs targeting this SNP were
516 designed using Benchling online tools. Synthesized oligos were then cloned into pBA904
517 vector backbone containing dCas9-KRAB and lentiviruses was packaged as described
518 above. For the CRISPR interference experiment, PSMCs cells were seeded into 6 well
519 plate (8×10^5 cells /well). The next day, cells were transduced with the virus for 12 hours
520 with 8 $\mu\text{g}/\text{mL}$ polybrene. The cells were cultured for an additional 5 days with medium
521 change until RNA was extracted. GuideRNA sequences are listed in Supplementary
522 Table 6.

523

524 Primary cell culture and sample processing

525

526 Primary human pulmonary artery smooth muscle cells (PASMC) obtained from Dr.
527 Rabenovich were originally isolated from pulmonary arteries ($< 1\text{mm}$) harvested from
528 unused donor lungs all obtained de-identified from the Pulmonary Hypertension
529 Breakthrough Initiative (<https://ipahresearch.org/phbi-research/>). For the experiments,
530 total RNA was isolated from confluent cells at passage 5 and 6.

531 Statistics and reproducibility for the functional studies

532 All statistical analyses were conducted using GraphPad Prism software version 9
533 (Dotmatics Inc). Difference between two groups were determined using an unpaired two-
534 tailed Student's t-test. Differences between multiple groups were evaluated by one-way
535 analysis of variance (ANOVA) followed by Dunnett's post-hoc test after the sample
536 distribution was tested for normality. P-values < 0.05 were considered statistically
537 significant. All error bars represent standard error of the mean. Number of stars for the P-
538 values in the graphs: *** P < 0.001; ** P < 0.01; * P < 0.05. No statistical method was
539 used to predetermine sample size, which was based on extensive prior experience with
540 this model.

541 542 Data and code availability

543
544 Individual-level data for can be accessed on successful application for cohorts used in
545 this study. The FinnGen individual level data may be accessed through applications to
546 the Finnish Biobanks' FinnBB portal, Fingenious (www.finbb.fi). For the individual level
547 data of theUKB, applications can be made through the UKB portal at
548 <https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access>. For MGB,
549 individual level data are available from the Mass General Brigham Human Research
550 Office/Institutional Review Board at Mass General Brigham (contact located at
551 <https://www.partners.org/Medical-Research/Support-Offices/Human-Research->

552 Committee-IRB/Default.aspx) for researchers who meet the criteria for access to
553 confidential data. Lastly, for the EstBB, preliminary inquiries to access individual level
554 data for scientific research can be send to releases@ut.ee.

555 Summary level data is available upon reasonable request.

556

557 Conflicts of Interest

558

559 The authors declare no competing interests.

560

561 Acknowledgments

562

563 This work was supported by the Instrumentarium Science Foundation (230041), the
564 Academy of Finland (340539), Doctoral Programme Brain and Mind (University of
565 Helsinki). We want to acknowledge the FinnGen study and the FinnGen team for their
566 contribution. We would like to thank the UK Biobank and the Mass General Brigham
567 Biobank participants and staff for making this work possible. We also want to
568 acknowledge the participants of the Estonian Biobank for their contributions. The
569 Estonian Genome Center analyses were partially carried out in the High Performance
570 Computing Center, University of Tartu.

571 The FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016
572 and UH4386/31/2016) and the following industry partners: AbbVie Inc., AstraZeneca UK
573 Ltd, BiogenMA Inc., Bristol Myers Squibb, Genentech Inc., Merck Sharp Dohme Corp,

574 Pfizer Inc., Glaxo-SmithKline Intellectual Property Development Ltd., Sanofi US
575 Services Inc., Maze Therapeutics Inc., Janssen Biotech Inc, Novartis Pharma AG, and
576 Boehringer Ingelheim. Following biobanks are acknowledged for delivering biobank
577 samples to FinnGen: Auria Biobank (www.auria.fi/biopankki), THL Biobank
578 (www.thl.fi/biobank), Helsinki Biobank (www.helsinginbiopankki.fi), Biobank Borealis of
579 Northern Finland ([https://www.ppsHP.fi/Tutkimus-ja-opetus/Biopankki/Pages/Biobank-](https://www.ppsHP.fi/Tutkimus-ja-opetus/Biopankki/Pages/Biobank-Borealis-briefly-in-English.aspx)
580 [Borealis-briefly-in-English.aspx](https://www.ppsHP.fi/Tutkimus-ja-opetus/Biopankki/Pages/Biobank-Borealis-briefly-in-English.aspx)), Finnish Clinical Biobank Tampere ([www.tays.fi/en-](http://www.tays.fi/en-US/Research/and/development/Finnish/Clinical/Biobank/Tampere)
581 [US/Research/and/development/Finnish/Clinical/Biobank/Tampere](http://www.tays.fi/en-US/Research/and/development/Finnish/Clinical/Biobank/Tampere)), Biobank of Eastern
582 Finland (www.ita-suomenbiopankki.fi/en), Central Finland Biobank ([www.ksshP.fi/fi-](http://www.ksshP.fi/fi-FI/Potilaalle/Biopankki)
583 [FI/Potilaalle/Biopankki](http://www.ksshP.fi/fi-FI/Potilaalle/Biopankki)), Finnish Red Cross Blood Service Biobank
584 (www.veripalvelu.fi/verenluovutus/biopankkitoiminta) and Terveystalo Biobank
585 (www.terveystalo.com/fi/Yritystietoa/Terveystalo-Biopankki/Biopankki/). All Finnish
586 Biobanks are members of BBMRI.fi infrastructure (www.bbmri.fi) and FINBB biobank
587 cooperative (<https://finbb.fi/>) is the coordinator of the BBMRI-ERIC operations in Finland
588 covering all Finnish biobanks.

589 The work of the Estonian Genome Center, University of Tartu was funded by the
590 European Union through Horizon 2020 research and innovation program under grants
591 no. 810645 and 894987, through the European Regional Development Fund projects
592 GENTRANSMED (2014-2020.4.01.15-0012), MOBEC008, MOBERA21 and Estonian
593 Research Council Grant PRG1291

References

1. Mathias, C.J., Owens, A., Iodice, V. & Hakim, A. Dysautonomia in the Ehlers-Danlos syndromes and hypermobility spectrum disorders-With a focus on the postural tachycardia syndrome. *Am. J. Med. Genet. C. Semin. Med. Genet.* 187(4), 510-519 (2021).
2. Nawaz, I., Nawaz, Y., Nawaz, E., Manan, M.R. & Mahmood, A. Raynaud's Phenomenon: Reviewing the Pathophysiology and Management Strategies. *Cureus* 14(1), (2022).
3. Garner, R., Kumari, R., Lanyon, P., Doherty, M. & Zhang, W. Prevalence, risk factors and associations of primary Raynaud's phenomenon: systematic review and meta-analysis of observational studies. *BMJ Open* 5(3), (2015).
4. World Health Organization. (2004). ICD-10: international statistical classification of diseases and related health problems: tenth revision, 2nd ed. World Health Organization. <https://apps.who.int/iris/handle/10665/42980>
5. Mizuno, R., Fujimoto, S., Saito, Y. & Nakamura, S. Cardiac Raynaud's phenomenon induced by cold provocation as a predictor of long-term left ventricular dysfunction and remodelling in systemic sclerosis: 7-year follow-up study. *Eur. J. Heart Fail* 12(3), 268-275 (2010).
6. Xia, Y.K., Tu, S.H., Hu, Y.H., Wang, Y., Chen, Z., Day, H.T. & Ross, K. Pulmonary hypertension in systemic lupus erythematosus: a systematic review and analysis of 642 cases in Chinese population. *Rheumatol. Int.* 33(5), 1211-1217 (2013).
7. Vonk, M.C., Vandecasteele, E. & van Dijk, A.P. Pulmonary hypertension in connective tissue diseases, new evidence and challenges. *Eur. J. Clin. Invest.* 51(4), (2021).
8. Haque, A., Kiely, D.G., Kovacs, G., Thompson, A.A.R. & Condliffe, R. Pulmonary hypertension phenotypes in patients with systemic sclerosis. *Eur. Respir. Rev.* 30(161), (2021).
9. Denton, C. P. & Khanna, D. K. Systemic sclerosis. *Lancet* 390, 1685–1699 (2017).
10. Evans, M., Barry, M., Im, Y., Brown, A. & Jason, L.A. An investigation of symptoms predating CFS onset. *J. Prev. Interv. Community* 43(1), 54-61 (2015).
11. Giuggioli, D., Spinella, A., de Pinto, M., Mascia, M.T. & Salvarani, C. From Raynaud Phenomenon to Systemic Sclerosis in COVID-19: A Case Report. *Adv. Skin Wound Care* 35(2), 123-124 (2022).
12. Curtiss, P., Svigos, K., Schwager, Z., Lo Sicco, K. & Franks Jr., A.G., Part I: Epidemiology, Pathophysiology, and Clinical Considerations of Primary and Secondary Raynaud's Phenomenon, *Journal of the American Academy of Dermatology* (2022).
13. Cherkas, L.F., Williams, F.M., Carter, L., Howell, K., Black, C.M., Spector, T.D. & MacGregor, A.J. Heritability of Raynaud's phenomenon and vascular

- responsiveness to cold: a study of adult female twins. *Arthritis Rheum.* 57(3), 524-528 (2007).
14. Hur, Y.M., Chae, J.H., Chung, K.W., Kim, J.J., Jeong, H.U., Kim, J.W., Seo, S.Y. & Kim, K.S. Feeling of cold hands and feet is a highly heritable phenotype. *Twin Res. Hum. Genet.* 15(2), 166-169 (2012).
 15. Maricq, H.R., Carpentier, P.H., Weinrich, M.C., Keil, J.E., Franco, A., Drouet, P., Ponçot, O.C. & Maines, M.V. Geographic variation in the prevalence of Raynaud's phenomenon: Charleston, SC, USA, vs Tarentaise, Savoie, France. *J. Rheumatol.* 20(1), 70-76 (1993).
 16. Zülch, A., Becker, M.B. & Gruss, P. Expression pattern of *Ir1* and *Ir2* during mouse digit development. *Mech. Dev.* 106(1-2), 159-162 (2001).
 17. Klarin, D., Lynch, J., Aragam, K., Chaffin, M., Assimes, T.L., Huang, J., Lee, K.M., Shao, Q., Huffman, J.E., Natarajan, P., et al. Genome-wide association study of peripheral artery disease in the Million Veteran Program. *Nat. Med.* 25(8), 1274-1279 (2019).
 18. Chen, K., Pittman, R.N. & Popel, A.S. Nitric oxide in the vasculature: where does it come from and where does it go? A quantitative perspective. *Antioxid Redox Signal.* 10(7), 1185-1198 (2008).
 19. Luiking, Y.C., Ten Have, G.A., Wolfe, R.R. & Deutz, N.E. Arginine de novo and nitric oxide production in disease states. *Am. J. Physiol. Endocrinol. Metab.* 303(10), 1177-1189 (2012).
 20. Bleakley, C., Hamilton, P.K., Pumb, R., Harbinson, M. & McVeigh, G.E. Endothelial Function in Hypertension: Victim or Culprit? *J. Clin. Hypertens. (Greenwich)* 17(8), 651-654 (2015).
 21. Astle, W.J., Elding, H., Jiang, T., Allen, D., Ruklisa, D., Mann, A.L., Mead, D., Bouman, H., Riveros-Mckay, F., Kostadima, M.A., et al. The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease. *Cell* 167(5), 1415-1429 (2016).
 22. Zhu, Z., Wang, X., Li, X., Lin, Y., Shen, S., Liu, C.L., Hobbs, B.D., Hasegawa, K., Liang, L., International COPD Genetics Consortium, Boezen, H.M., Camargo, C.A. Jr., Cho, M.H. & Christiani, D.C. Genetic overlap of chronic obstructive pulmonary disease and cardiovascular disease-related traits: a large-scale genome-wide cross-trait analysis. *Respir. Res.* 20(1), (2019).
 23. Reid, J.L. Alpha-adrenergic receptors and blood pressure control. *Am. J. Cardiol.* 57(9), 6-12 (1986).
 24. Altman, J.D., Trendelenburg, A.U., MacMillan, L., Bernstein, D., Limbird, L., Starke, K., Kobilka, B.K. & Hein, L. Abnormal regulation of the sympathetic nervous system in alpha2A-adrenergic receptor knockout mice. *Mol. Pharmacol.* 56(1), 154-161 (1999).
 25. Dinunno, F.A., Eisenach, J.H., Dietz, N.M. & Joyner, M.J. Post-junctional alpha-adrenoceptors and basal limb vascular tone in healthy men. *J. Physiol.* 540(Pt 3), 1103-1110 (2002).

26. Chotani, M.A., Mitra, S., Su, B.Y., Flavahan, S., Eid, A.H., Clark, K.R., Montague, C.R., Paris, H., Handy, D.E. & Flavahan, N.A. Regulation of alpha(2)-adrenoceptors in human vascular smooth muscle cells. *Am. J. Physiol. Heart Circ. Physiol.* 286(1), 59-67 (2004).
27. Brum, P.C., Hurt, C.M., Shcherbakova, O.G., Kobilka, B. & Angelotti, T. Differential targeting and function of alpha2A and alpha2C adrenergic receptor subtypes in cultured sympathetic neurons. *Neuropharmacology* 51(3), 397-413 (2006).
28. Kurnik, D., Muszkat, M., Li, C., Sofowora, G.G., Friedman, E.A., Scheinin, M., Wood, A.J. & Stein, C.M. Genetic variations in the $\alpha(2A)$ -adrenoreceptor are associated with blood pressure response to the agonist dexmedetomidine. *Circ. Cardiovasc. Genet.* 4(2), 179-187 (2011).
29. Docherty, JR. Subtypes of functional alpha1- and alpha2-adrenoceptors. *Eur. J. Pharmacol.* 361(1), 1-15 (1998).
30. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. *Nature* 489(7414), 57-74 (2012).
31. Villa, N., Walker, L., Lindsell, C.E., Gasson, J., Iruela-Arispe, M.L. & Weinmaster, G. Vascular expression of Notch pathway receptors and ligands is restricted to arterial vessels. *Mech. Dev.* 108(1-2), 161-164 (2001).
32. Liu, H., Zhang, W., Kennard, S., Caldwell, R.B. & Lilly, B. Notch3 is critical for proper angiogenesis and mural cell investment. *Circ. Res.* 107(7), 860-870 (2010).
33. Bailey, S.R., Eid, A.H., Mitra, S., Flavahan, S. & Flavahan, N.A. Rho kinase mediates cold-induced constriction of cutaneous arteries: role of alpha2C-adrenoceptor translocation. *Circ. Res.* 94(10), 1367-1374 (2004).
34. Bailey, S.R., Mitra, S., Flavahan, S. & Flavahan, N.A. Reactive oxygen species from smooth muscle mitochondria initiate cold-induced constriction of cutaneous arteries. *Am. J. Physiol. Heart Circ. Physiol.* 289(1), 243-250 (2005).
35. Freedman, R.R., Moten, M., Migály, P. & Mayes, M. Cold-induced potentiation of alpha 2-adrenergic vasoconstriction in primary Raynaud's disease. *Arthritis Rheum.* 36(5), 685-690 (1993).
36. Freedman, R.R., Baer, R.P. & Mayes, M.D. Blockade of vasospastic attacks by alpha 2-adrenergic but not alpha 1-adrenergic antagonists in idiopathic Raynaud's disease. *Circulation* 92(6), 1448-1451 (1998).
37. MacMillan, L.B., Hein, L., Smith, M.S., Piascik, M.T. & Limbird, L.E. Central hypotensive effects of the alpha2a-adrenergic receptor subtype. *Science* 273(5276), 801-803 (1996).
38. Chotani, M.A., Flavahan, S., Mitra, S., Daunt, D. & Flavahan, N.A. Silent alpha(2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. *Am. J. Physiol. Heart Circ. Physiol.* 278(4), 1075-1083 (2000).
39. Jeyaraj, S.C., Chotani, M.A., Mitra, S., Gregg, H.E., Flavahan, N.A. & Morrison, K.J. Cooling evokes redistribution of alpha2C-adrenoceptors from Golgi to

- plasma membrane in transfected human embryonic kidney 293 cells. *Mol. Pharmacol.* 60(6), 1195-2000 (2001).
40. Chotani, M.A. & Flavahan, N.A. Intracellular $\alpha(2C)$ -adrenoceptors: storage depot, stunted development or signaling domain? *Biochim. Biophys. Acta.* 1813(8), 1495-1503 (2011).
 41. Landry, G.J. Current medical and surgical management of Raynaud's syndrome. *J. Vasc. Surg.* 57(6), 1710-1716 (2013).
 42. Hartmann, S., Yasmeen, S., Jacobs, B.M, Denaxas, S., Pirmohamed, M., Gamazon, E.R., Caulfield, M.J, Genes & Health Research Team, Hemingway, H. & Pietzner, M., Langenberg, C. ADRA2A and IRX1 are putative risk genes for Raynaud's phenomenon. Preprint at medRxiv <https://doi.org/10.1101/2022.10.19.22281276> (2023).
 43. Langer, S.Z. Presynaptic regulation of the release of catecholamines. *Pharmacol. Rev.* 32(4), 337-362 (1980).
 44. Ahmad, A., Dempsey, S.K., Daneva, Z., Azam, M., Li, N., Li, P.L. & Ritter, J.K. Role of Nitric Oxide in the Cardiovascular and Renal Systems. *Int. J. Mol. Sci.* 19(9), 2605 (2018).
 45. Tucker, A.T., Pearson, R.M., Cooke, E.D. & Benjamin, N. Effect of nitric-oxide-generating system on microcirculatory blood flow in skin of patients with severe Raynaud's syndrome: a randomised trial. *Lancet* 354(9191), 1670-1675 (1999).
 46. Herrick, A. The pathogenesis, diagnosis and treatment of Raynaud phenomenon. *Nat. Rev. Rheumatol.* 8, 469–479 (2012).
 47. Hughes, M. & Herrick, A.L. Raynaud's phenomenon. *Best Pract. Res. Clin. Rheumatol.* 30(1), 112-132 (2016).
 48. Luo, Y., Wang, Y., Wang, Q., Xiao, R. & Lu, Q. Systemic sclerosis: genetics and epigenetics. *J. Autoimmun.* 41, 161-167 (2013).
 49. Grotewold, L. & R  ther, U. The Fused toes (Ft) Mouse Mutation Causes Anteroposterior and Dorsoventral Polydactyly. *Dev. Biol.* 251(1), 129-141 (2002).
 50. D  az-Hern  ndez, M.E., Rios-Flores, A.J., Abarca-Buis, R.E., Bustamante, M. & Chimal-Monroy, J. Molecular Control of Interdigital Cell Death and Cell Differentiation by Retinoic Acid during Digit Development. *J. Dev. Biol.* 2(2), 138-157 (2014).
 51. Hu, W., Xin, Y., Zhang, L., Hu, J., Sun, Y. & Zhao, Y. Iroquois Homeodomain transcription factors in ventricular conduction system and arrhythmia. *Int. J. Med. Sci.* 15(8), 808-815 (2018).
 52. Jung, I.H., Jung, D.E., Chung, Y.Y., Kim, K.S. & Park, S.W. Iroquois Homeobox 1 Acts as a True Tumor Suppressor in Multiple Organs by Regulating Cell Cycle Progression. *Neoplasia* 21(10), 1003-1014 (2019).
 53. K  ster, M.M., Schneider, M.A., Richter, A.M., Richtmann, S., Winter, H., Kriegsmann, M., Pullamsetti, S.S., Stiewe, T., Savai, R., Muley, T. & Dammann, R.H. Epigenetic Inactivation of the Tumor Suppressor IRX1 Occurs Frequently in Lung Adenocarcinoma and Its Silencing Is Associated with Impaired Prognosis. *Cancers (Basel)* 12(12), 3528 (2020).

54. Lee, J.Y., Lee, W.K., Park, J.Y. & Kim, D.S. Prognostic value of Iroquois homeobox 1 methylation in non-small cell lung cancers. *Genes Genomics* 42(5), 571-579 (2020).
55. Young, J., Ménétrey, J. & Goud, B. RAB6C is a retrogene that encodes a centrosomal protein involved in cell cycle progression. *J. Mol. Biol.* 397(1), 69-88 (2010).
56. Zhen, Y., Pavez, M. & Li, X. The role of Pcdh10 in neurological disease and cancer. *J. Cancer Res. Clin. Oncol.*, (2023).
57. Terkelsen, T., Pernemalm, M., Gromov, P., Børresen-Dale, A.L., Krogh, A., Haakensen, V.D., Lethiö, J., Papaleo, E. & Gromova, I. High-throughput proteomics of breast cancer interstitial fluid: identification of tumor subtype-specific serologically relevant biomarkers. *Mol. Oncol.* 15(2), 429-461 (2021).
58. Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L.T., Sharp, K., Motyer, A., Vukcevic, D., Delaneau, O., O'Connell, J., et al. The UK Biobank resource with deep phenotyping and genomic data. *Nature* 562, 203–209 (2018).
59. Leitsalu, L., Haller, T., Esko, T., Tammesoo, M.L., Alavere, H., Snieder, H., Perola, M., Ng, P.C., Mägi, R., Milani, L., Fischer, K. & Metspalu, A. Cohort Profile: Estonian Biobank of the Estonian Genome Center, University of Tartu. *Int. J. Epidemiol.* 44(4), 1137-1147 (2015).
60. Karlson, E., Boutin, N., Hoffnagle, A. & Allen, N. Building the Partners HealthCare Biobank at Partners Personalized Medicine: informed consent, return of research results, recruitment lessons and operational considerations. *J. Pers. Med.* 6(1), (2016).
61. Boutin, N., Holzbach, A., Mahanta, L., Aldama, J., Cerretani, X., Embree, K., Leon, I., Rathi, N. & Vickers, M. The information technology infrastructure for the translational genomics core and the partners biobank at partners personalized medicine. *J. Pers. Med.* 6(1), 1-6 (2016).
62. Boutin, N.T., Mathieu, K., Hoffnagle, A.G., Allen, N.L., Castro, V.M., Morash, M., O'Rourke, P., Hohmann, E., Herring, N., Bry, L., et al. Implementation of electronic consent at a Biobank: an opportunity for precision medicine research. *J. Pers. Med.* 6(2), 1-11 (2016).
63. Dashti, H.S., Cade, B.E., Stutaite, G., Saxena, R., Redline, S. & Karlson, E.W. Sleep Health, Diseases, and Pain Syndromes: findings from an electronic health record biobank. *Sleep* 44(3) (2020).
64. Kurki, M.I., Karjalainen, J., Palta, P., Sipilä, T.P., Kristiansson, K., Donner, K.M., Reeve, M.P., Laivuori, H., Aavikko, M., Kaunisto, M.A., et al. FinnGen provides genetic insights from a well-phenotyped isolated population. *Nature* 613(7944), 508-518 (2023).
65. Browning, B.L., Tian, X., Zhou, Y. & Browning, S.R. Fast two-stage phasing of large-scale sequence data. *Am. J. Hum. Genet.* 108(10), 1880-1890 (2021).
66. Manichaikul, A., Mychaleckyj, J.C., Rich, S.S., Daly, K., Sale, M. & Chen, W.M. Robust relationship inference in genome-wide association studies. *Bioinformatics* 26(22), 2867-2873 (2010).

67. The 1000 Genomes Project Consortium, *Nature* 526, 68-74 (2015).
68. Mbatchou, J., Barnard, L., Backman, J., Marcketta, A., Kosmicki, J.A., Ziyatdinov, A., Benner, C., O'Dushlaine, C., Barber, M., Boutkov, B., et al. Computationally efficient whole-genome regression for quantitative and binary traits. *Nat. Genet.* 53, 1097–1103 (2021).
69. Alkes, L., Price, A.L., Weale, M.E., Patterson, N., Myers, S.R., Need, A.C., Shianna, K.V., Ge, D., Rotter, J.I., Torres, E., et al. Long-Range LD Can Confound Genome Scans in Admixed Populations. *Am. J. Hum. Gen.* 83, 132-135 (2008).
70. Boughton, A.P., Welch, R.P., Flickinger, M., VandeHaar, P., Taliun, D., Abecasis, G.R. & Boehnke, M. LocusZoom.js: interactive and embeddable visualization of genetic association study results. *Bioinformatics* 37(18), 3017-3018 (2021).
71. GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across human tissues. *Science* 369(6509), 1318-1330 (2020).
72. Wang, G., Sarkar, A., Carbonetto, P., Stephens, M. A Simple New Approach to Variable Selection in Regression, with Application to Genetic Fine Mapping. *Journal of the Royal Statistical Society Series B: Statistical Methodology*, Volume 82, Issue 5, December 2020, Pages 1273–1300.
73. Wallace, C. A more accurate method for colocalisation analysis allowing for multiple causal variants. *PLoS Genet.* 17(9), (2021).
74. Liu, B., Gludemans, M.J., Rao, A.S., Ingelsson, E. & Montgomery, S.B. Abundant associations with gene expression complicate GWAS follow-up. *Nat. Genet.* 51(5), 768-769 (2019).
75. Zhao, Q., Dacre, M., Nguyen, T., Pjanic, M., Liu, B., Iyer, D., Cheng, P., Wirka, R., Kim, J.B., Fraser, H.B. & Quertermous, T. Molecular mechanisms of coronary disease revealed using quantitative trait loci for TCF21 binding, chromatin accessibility, and chromosomal looping. *Genome Biol.* 21(1), 135 (2020).